0000899243-23-002272.txt : 20230120
0000899243-23-002272.hdr.sgml : 20230120
20230120181227
ACCESSION NUMBER: 0000899243-23-002272
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230118
FILED AS OF DATE: 20230120
DATE AS OF CHANGE: 20230120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khayal Tamer I
CENTRAL INDEX KEY: 0001430462
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38891
FILM NUMBER: 23542153
MAIL ADDRESS:
STREET 1: TRANSMEDICS INC
STREET 2: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TransMedics Group, Inc.
CENTRAL INDEX KEY: 0001756262
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
BUSINESS PHONE: 9785520900
MAIL ADDRESS:
STREET 1: 200 MINUTEMAN ROAD
CITY: ANDOVER
STATE: MA
ZIP: 01810
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-18
0
0001756262
TransMedics Group, Inc.
TMDX
0001430462
Khayal Tamer I
C/O TRANSMEDICS GROUP, INC.
200 MINUTEMAN ROAD
ANDOVER
MA
01810
0
1
0
0
Chief Commercial Officer
Common Stock
2023-01-18
4
M
0
1300
16.00
A
2600
D
Common Stock
2023-01-18
4
S
0
1300
65.11
D
1300
D
Common Stock
2023-01-20
4
M
0
5558
16.00
A
6858
D
Common Stock
2023-01-20
4
S
0
5558
65.21
D
1300
D
Common Stock
11051
I
By the Tamer Ibrahim Ahmed Khayal Trust
Common Stock
24776
I
By the Khayal Family 2021 Irrevocable Trust
Stock Option (Right to Buy)
16.00
2023-01-18
4
M
0
1300
0.00
D
2029-05-01
Common Stock
1300
52985
D
Stock Option
(Right to Buy)
16.00
2023-01-20
4
M
0
5558
0.00
D
2029-05-01
Common Stock
5558
47427
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.00 to $65.30, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.00 to $65.56, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option vests in equal monthly installments over four years beginning on the date of grant, May 1, 2019.
By: /s/ Stephen Gordon, Attorney-in-Fact
2023-01-20